1248 Management’s Bristol-Myers Squibb BMY Stock Holding History

1248 Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-151	Closed	-$9.21K	–	169
2025 Q1	$9.21K	Buy	+151	New	+$8.8K	﹤0.01%	161

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

1248 Management's BMY Position: Q2 2025 in Review

1248 Management sold out of Bristol-Myers Squibb (BMY) in Q2 2025, closing a stake of 151 shares — an estimated $9.21K sold.

1248 Management first reported a position in BMY in Q1 2025 and held it in 1 quarter. The position peaked at $9.21K in Q1 2025. 2,293 funds tracked by Wall St. Rank hold BMY as of Q2 2025.

1248 Management reported no remaining Bristol-Myers Squibb position as of Q2 2025 after selling out during the quarter.
1248 Management sold 151 Bristol-Myers Squibb shares in Q2 2025, an estimated $9.21K.
1248 Management first reported a position in Bristol-Myers Squibb in Q1 2025 and held it in 1 quarter.
1248 Management's Bristol-Myers Squibb position peaked at $9.21K in Q1 2025.
2,293 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2025.

Based on 1248 Management's 13F filing for Q2 2025, filed 18 Aug 2025.